SkinmedPub Date : 2024-09-17eCollection Date: 2024-01-01
Tamara Gracia-Cazaña, Victoria Fuentelsaz, Alba Navarro-Bielsa, Emilio Giner-Serret, Francisco Javier García-Latasa
{"title":"与阿达木单抗治疗相关的斑秃：TNF-α 在抑制纤维化中的作用","authors":"Tamara Gracia-Cazaña, Victoria Fuentelsaz, Alba Navarro-Bielsa, Emilio Giner-Serret, Francisco Javier García-Latasa","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Anti-tumor necrosis factor alpha (anti-TNF-α) comprises a group of drugs that inhibit the action of cytokine TNF-α, and are used to treat diseases mainly caused by this cytokine. An increase in cutaneous adverse events has been observed with similar anti-TNF biologic treatments frequently used in clinical practice.</p>","PeriodicalId":94206,"journal":{"name":"Skinmed","volume":"22 4","pages":"296-297"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Morphea Associated with Adalimumab Treatment: The Role of TNF-α in Inhibition of Fibrosis.\",\"authors\":\"Tamara Gracia-Cazaña, Victoria Fuentelsaz, Alba Navarro-Bielsa, Emilio Giner-Serret, Francisco Javier García-Latasa\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anti-tumor necrosis factor alpha (anti-TNF-α) comprises a group of drugs that inhibit the action of cytokine TNF-α, and are used to treat diseases mainly caused by this cytokine. An increase in cutaneous adverse events has been observed with similar anti-TNF biologic treatments frequently used in clinical practice.</p>\",\"PeriodicalId\":94206,\"journal\":{\"name\":\"Skinmed\",\"volume\":\"22 4\",\"pages\":\"296-297\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skinmed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skinmed","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Morphea Associated with Adalimumab Treatment: The Role of TNF-α in Inhibition of Fibrosis.
Anti-tumor necrosis factor alpha (anti-TNF-α) comprises a group of drugs that inhibit the action of cytokine TNF-α, and are used to treat diseases mainly caused by this cytokine. An increase in cutaneous adverse events has been observed with similar anti-TNF biologic treatments frequently used in clinical practice.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
